The genetics of MLL leukemogenesis

October 16, 2007

In the November 1st issue of G&D, Dr. Michael Cleary (Stanford University School of Medicine) and colleagues identify the gene Meis1 as a critical player in the establishment of leukemia stem cells, and the development of MLL leukemia.

Mixed lineage leukemia (MLL) is a distinctive type of leukemia - distinguished from the more prevalent acute lymphoblastic leukemia (ALL) by the presence of a break and rearrangement of chromosome number 11. The design of effective therapies to combat MLL leukemia depends upon the understanding of the unique genetic signature that underlies this disease.

This chromosomal translocation that characterizes MLL activates the histone methyltranferase enzyme called MLL, inducing it to turn-on downstream gene targets that transform blood progenitor cells into leukemia stem cells (LSCs).

While some of the downstream targets of MLL are known (Hox genes, for example), the genetic changes that are sufficient to drive MLL leukomogeneis have remained elusive. Dr. Cleary and colleagues focused their work on another group of proteins that are mis-expressed in MLL leukemias: the TALE (three-amino-acid loop extension) class of proteins.

The researchers found that one gene in particular - called Meis1 - is required for leukemia stem cell maintenance. In fact, the researchers showed that Meis1 regulates many important biological properties of the disease including differentiation arrest, cycling activity, in vivo progression and self-renewal of LSCs.

Dr. Cleary is confident that "The critical role of Meis1 and other TALE class proteins in MLL leukemia stem cells provides a promising avenue for future studies to design more selective therapies for this poor prognosis subtype of leukemia."
-end-


Cold Spring Harbor Laboratory

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.